fda compounding semaglutide warning november 2025 Warns on Certain Forms of Compounded FDA and Novo Nordisk Warned

J Hum Hypertens

The warning label on the medication now cautions that the medication may cause intestinal blockage

Non-GLP-1 conditions are not managed within the scope of the platforms telehealth services

This mechanism is thought to be responsible for Retatrutides notable efficacy in resolving hepatic steatosis (fatty liver disease)

Introductory or promotional pricing, including first month offers, are not governed by the same price per dose policy and only apply to full-price products as listed on the website

Retatrutide is increasingly referenced in research exploring metabolic-related pathways, multi-compound protocols, and peptide-based study models, and is commonly included in advanced research setups